@article{3022613,
    title = "Report on the joint EFPIA, DIA and EMEA pharmacogenetics workshop: Moving toward clinical application",
    author = "McCarthy, A. and Kerr, M. and Abadie, E. and Chibout, S.-D. and Imbert, G. and Cohen, N. and Drakoulis, N. and Knudsen, L.E. and Flamion, B. and Hashimoto, L. and Verhoofstad, W. and Kreutz, G. and McHale, D. and Mitchell, T. and Papaluca Amati, M. and Roberts, R. and Shaw, P. and Stuerzebecher, C.S. and Townend, D.",
    journal = "Current Pharmacogenomics",
    year = "2004",
    volume = "5",
    number = "6",
    pages = "731-739",
    issn = "1570-1603",
    doi = "10.1517/14622416.5.6.731",
    keywords = "alosetron;  antidiabetic agent;  atomoxetine;  BCR ABL protein;  cytochrome P450 2D6;  epidermal growth factor receptor 2;  imatinib;  serotonin transporter;  serotonin uptake inhibitor;  trastuzumab, article;  attention deficit disorder;  breast cancer;  chronic myeloid leukemia;  clinical study;  clinical trial;  constipation;  depression;  diabetes mellitus;  diagnostic test;  drug absorption;  drug approval;  drug design;  drug efficacy;  drug industry;  drug metabolism;  drug safety;  enteritis;  European Union;  fluorescence in situ hybridization;  food and drug administration;  health care policy;  health program;  human;  immunohistochemistry;  ischemic colitis;  legal aspect;  medical decision making;  medical ethics;  medical research;  medical society;  pharmacogenetics;  postmarketing surveillance;  social aspect;  workshop, Clinical Trials;  Decision Making;  Drug Design;  Drug Industry;  Humans;  Pharmacogenetics;  Product Surveillance, Postmarketing"
}